



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com) <http://www.wjgnet.com>

---

**Name of Journal:** *World Journal of Clinical Urology*

**ESPS Manuscript NO:** 25628

**Manuscript Type:** Editorial

Response to Reviewers:

- 1.) The first two comments in page 1 say “offer”. We are not entirely sure what this means. I edited the first and second lines to read:  
Name of Journal: *World Journal of Clinical Urology*  
Manuscript type: Editorial
- 2.) The reviewers wanted the country and postal code added to the signature block; this was performed. Now it is:  
Lahey Hospital and Medical Center, Institute of Urology, USA, Burlington, MA 01805
- 3.) The reviewers wanted an author’s contribution section. This was added and now it is:  
Patel CK played an integral role in the conception of the article, acquisition of literature and also drafted the manuscript. Mourtzinou AP is the senior author who reviewed and made critical revisions to the manuscript.
- 4.) The reviewers wanted a signed PDF of a conflict of interest statement. This is included in the new set of submitted documents.
- 5.) The reviewers wanted more detail for the corresponding author. This was added and now reads:  
Chintan K. Patel, M.D, Resident in Urology, Institute of Urology, Lahey Hospital and Medical Center, 41 Burlington Mall Rd., Burlington, MA 01805 United States
- 6.) The reviewers wanted a core tip in audio format. The core tip has been lengthened from the original version and the audio file will be with the other documents. The core tip now reads:  
OAB remains a highly prevalent and frequently, a recalcitrant constellation of symptoms. For patients who are refractory to oral medical therapy, there is sufficient level I evidence to support the use of onabotulinum toxin A injection therapy. It is a safe and very effective 2nd line treatment for OAB, even in the elderly population. The suggested FDA-approved dose is 100 U to maximize the benefits and minimize the adverse effects of this therapy. Risks of the intradetrusor injection of onabotulinum toxin A include UTI, increased PVR, urinary retention which may lead to necessity of self catheterization for a period of time.
- 7.) The reviewers wanted the superscript of each reference in []. This was performed throughout the document.